A Study of BMS-986166 or Branebrutinib for the Treatment of Participants With Atopic Dermatitis

ClinicalTrials.gov ID: NCT05014438

Public ClinicalTrials.gov record NCT05014438. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 24, 2026, 6:51 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2, Randomized, Double-blinded, Placebo-controlled, 5 Parallel-group Study of BMS-986166 or Branebrutinib for the Treatment of Patients With Moderate to Severe Atopic Dermatitis

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986166 and of branebrutinib, each versus placebo, for the treatment of participants with moderate to severe atopic dermatitis.

Study identification

NCT ID: NCT05014438
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: Bristol-Myers Squibb; Industry
Enrollment: 17 participants

Conditions and interventions

Conditions

Dermatitis, Atopic

Interventions

Drug · Other

Eligibility (public fields only)

Age range: 18 Years to 65 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Aug 17, 2021 (Actual)
Primary completion: Aug 22, 2022 (Actual)
Completion: Aug 22, 2022 (Actual)
Last update posted: Oct 18, 2023

2021 – 2022

United States locations

U.S. sites: 17
U.S. states: 11
U.S. cities: 17

Facility	City	State	ZIP	Site status
Local Institution - 0091	Fremont	California	94538	—
Local Institution - 0112	Brandon	Florida	33511	—
Local Institution - 0061	Coral Gables	Florida	33134	—
Local Institution - 0110	Margate	Florida	33063	—
Local Institution - 0006	Miami Lakes	Florida	33014	—
Local Institution	Tampa	Florida	33613	—
Local Institution - 0008	Skokie	Illinois	60077	—
Local Institution - 0081	Indianapolis	Indiana	46250	—
Local Institution - 0083	Louisville	Kentucky	40217	—
Dermatology and Skin Cancer Specialists, LLC	Rockville	Maryland	20850	—
Local Institution - 0051	Saint Joseph	Missouri	64506	—
Local Institution	New York	New York	10029	—
Local Institution - 0078	Philadelphia	Pennsylvania	19103	—
Local Institution - 0094	Pittsburgh	Pennsylvania	15213	—
The University of Texas Health Science Center at Houston	Bellaire	Texas	77401	—
Local Institution	San Antonio	Texas	78213	—
Local Institution - 0003	Morgantown	West Virginia	26505	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 25 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT05014438, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Oct 18, 2023 · Synced Oct 24, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT05014438 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →